BiotechTube
Home/MBX Biosciences/Kent Hawryluk
KH

Kent Hawryluk

President and Chief Executive Officer

MBX Biosciences

Therapeutic Areas

Endocrine DisordersMetabolic Disorders

MBX Biosciences Pipeline

DrugIndicationPhase
Canvuparatide (MBX 2109)Chronic Hypoparathyroidism (HP)Phase 2
Undisclosed PEP CandidatesVarious Endocrine and Metabolic DisordersDiscovery

Leadership Team at MBX Biosciences

RD
Richard DiMarchi, PhD
Scientific Co-Founder
View full MBX Biosciences profile